复方丹参滴丸联合重组人尿激酶原治疗急性ST段抬高型心肌梗死的临床研究

目的探讨复方丹参滴丸联合注射用重组人尿激酶原治疗急性ST段抬高型心肌梗死的临床疗效。方法选取2015年6月—2017年6月河南大学第一附属医院收治的急性ST段抬高型心肌梗死患者120例为研究对象,将所有患者随机分为对照组和治疗组,每组各60例。对照组给予注射用重组人尿激酶原,50 mg/次,先将20 mg加入到生理盐水10 m L,3 min内静脉推注完毕,然后30 mg加入到生理盐水90 m L,30 min内静脉滴注完毕。治疗组在对照组治疗的基础上口服复方丹参滴丸,10丸/次,3次/d。两组患者均持续治疗15 d。观察两组的临床疗效,比较两组的血管再通率和左心功能。结果治疗后,对照组和治疗组的总有效率分别为81.66%、96.67%,两组比较差异有统计学意义(P0.05)。治疗后,对照组血管再通率为83.33%;治疗组血管再通率为93.33%,两组血管再通率比较差异有统计学意义(P0.05)。治疗后,两组左心室舒张期末内径(LVEDD)、左心室射血分数(LVEF)均显著升高,同组治疗前后比较差异有统计学意义(P0.05);且治疗组左心功能指标明显高于对照组,两组比较差异具有统计学意义(P0.05)。结论复方丹参滴丸联合注射用重组人尿激酶原治疗急性ST段抬高型心肌梗死具有较好的临床疗效,显著提高血管再通率,改善左心功能,安全性较好,具有一定临床推广应用价值。

Clinical study on Compound Danshen Dripping Pills combined with reocmbinant human prourokinase in treatment of acute ST segment elevation myocardial infarction

Objective To investigate the effects of Compound Danshen Dripping Pills combined with Reocmbinant Human Prourokinase for injection in treatment of acute ST segment elevation myocardial infarction. Methods Patients (120 cases) with acute ST segment elevation myocardial infarction in the First Affiliated Hospital of Henan University from June 2015 to June 2017 were randomly divided into control and treatment groups, and each group had 60 cases. Patients in the control group were given Reocmbinant Human Prourokinase for injection, 50 mg/time, first 20 mg added into normal saline 10 mL, intravenous injection within 3 min, then 30 mg added into normal saline 90 mL, intravenous drip within 30 min. Patients in the treatment group were po administered with Compound Danshen Dripping Pills on the basis of the control group, 10 pills/time, three times daily. Patients in two groups were treated for 15 d. After treatment, the clinical efficacies were evaluated, and revascularization rate and left heart function in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 81.66% and 96.67%, respectively, and there was difference between two groups (P<0.05). After treatment, the revascularization rates in the control and treatment groups were 83.33% and 93.33%, respectively, and there was difference between two groups (P<0.05). After treatment, LVEDD and LVEF in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the left heart function indexes in the treatment group were significantly higher than those in the control group, with significant difference between two groups (P<0.05). Conclusion Compound Danshen Dripping Pills combined with Reocmbinant Human Prourokinase for injection has clinical curative effect in treatment of acute ST segment elevation myocardial infarction, can significantly increase revascularization rate, and improve the left heart function, with good safety, which has a certain clinical application value.